You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Classical Hodgkin Lymphoma

Showing 1 - 25 of 7,646
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma Trial in Cologne (Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Sep 19, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Hodgkin Lymphoma Trial in Salt Lake City (Axatilimab, Nivolumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Feb 1, 2023

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Nivolumab, Adriamycin, Vinblastine)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    University Hospital of Cologne
Aug 5, 2022

Classical Hodgkin Lymphoma Trial in Cologne (Tislelizumab)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Russian Federation
  • +1 more
Mar 3, 2023

Recurrent/Refractory Classical Hodgkin's Lymphoma Trial in Tianjin (AK105,Anrotinib HCl)

Enrolling by invitation
  • Recurrent/Refractory Classical Hodgkin's Lymphoma
  • AK105，Anrotinib hydrochloride
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 12, 2023

Classical Hodgkin Lymphoma Trial in Cologne (Pembrolizumab plus Chemotherapy (ICE or DHAP))

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Pembrolizumab plus Chemotherapy (ICE or DHAP)
  • Cologne, Germany
    1st Department of Medicine, Cologne University Hospital
Aug 5, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

Classical Hodgkin Lymphoma Trial in Charlottesville (Pembrolizumab, Doxorubicin, Vinblastine)

Recruiting
  • Classical Hodgkin Lymphoma
  • Charlottesville, Virginia
    University of Virginia
Jul 27, 2022

Hodgkin Lymphoma Trial in Moscow (Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Moscow, Russian Federation
    The Federal Budget-Funded Institution National Medical Surgical
Oct 31, 2022

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

Not yet recruiting
  • Hodgkin Lymphoma
  • No Intervention
  • Salvador, Bahia, Brazil
  • +5 more
Oct 23, 2023

Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)

Not yet recruiting
  • Hodgkin Lymphoma
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma Trial in Cologne (B-CAP, Brentuximab Vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • Cologne, Germany
    1st Dept. of Medicine, Cologne University Hospital
Aug 5, 2022

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022

Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

Recruiting
  • Classical Hodgkin Lymphoma
  • Refractory or Relapsed Classical Hodgkin Lymphoma
  • PD-1 inhibitor
  • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Allogeneic Hematopoietic Cell Transplantation For Classical

Active, not recruiting
  • Lymphoma
  • Non-Interventional
  • Princeton, New Jersey
  • +1 more
Mar 14, 2022

Classical Hodgkin Lymphoma Trial in Seattle (drug, other, biological)

Recruiting
  • Classical Hodgkin Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 8, 2022

Classical Hodgkin Lymphoma Trial in Guangzhou (Zimberelimab 240mg)

Recruiting
  • Classical Hodgkin Lymphoma
  • Zimberelimab 240mg
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-Sen University Cancer Ce
Jun 15, 2023

Intensive Monitoring Study on Tyvyt

Recruiting
  • Relapsed or Refractory Classical Hodgkin's Lymphoma
    • Beijing, China
      Peking Union Medical College Hospital
    Sep 14, 2022

    Classical Hodgkin Lymphoma Trial in China (Tislelizumab, Salvage Chemotherapy)

    Recruiting
    • Classical Hodgkin Lymphoma
    • Beijing, Beijing, China
    • +6 more
    Jan 4, 2022

    Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

    Recruiting
    • Relapsed Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Nivolumab
    • Pembrolizumab
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Jul 22, 2022